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TISSUE-ENGINEERED VASCULAR GRAFTS ALLOW NEOVESSEL FORMATION BY
RECRUITING ADJACENT VASCULAR TISSUE.
Adam Shoffner, Narutoshi Hibino, Gustavo Villalona, Nicholas Pietris, Daniel R. Duncan,
Jason D. Roh, Tai Yi, Lawrence W. Dobrucki, Dane Mejias, Rajendra Sawh-Martinez,
Jamie K. Harrington, Albert Sinusas, Diane S. Krause, Themis Kyriakides, W. Mark
Saltzman, Jordan S. Pober, Toshiharu Shin’oka, and Christopher K. Breuer.
Interdepartmental Program in Vascular Biology and Therapeutics, Yale University,
School of Medicine, New Haven, Connecticut, USA.

Hypothesis: Tissue Engineered Vascular Grafts (TEVGs) constructed by seeding cells
autologous bone marrow-derived mononuclear cells onto dissolvable scaffolding aid in the
recruitment of cells from either the host’s bone marrow or neighboring vasculature to
form the graft neotissue.
Methods: RT-PCR was performed on explanted grafts to detect presence of seeded cells.
FISH for Y chromosome was performed on female mice with male bone marrow transplant
along with female mice with implanted male-composite TEVG.
Results: The seeded cells on implanted TEVGs decrease precipitously from 4.37% to
0.02% from 6hr to 14 days. At 6 months post implantation composite graft TEVGs
displayed a high percentage of Y chromosome-positive cells adjacent to male inferior vena
cava tissue. Explanted grafts from female mice following male bone marrow transplant
revealed no neotissue positive for Y chromosome.
Discussion: TEVGs derive their neotissue from adjacent vasculature following
implantation that is mechanistically aided by the presence of seeded bone marrowderived mononuclear cells.
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Introduction:
In North America, Congenital Heart Defects (CHDs) continue to be the
leading cause of death within the infant population (1). Occurring in
approximately 0.8% of live births some CHDs are clinically non-significant,
however others are clearly associated with significant morbidity and
mortality (2). Many less severe CHDs are readily controllable with
observation and medical therapy. However, more complicated defects such
as tetrology of Fallot and single ventricle defects require surgical methods
for the establishment of physiologic blood flow (3).

The atria, ventricles, valves, and great vessels can all be anomalous in
CHDs (4). Occasionally a primary repair of the defect is possible. However,
often the use of a prosthetic graft is necessary for anatomical continuity in
cases of greater complexity such as in single ventricle anomalies. These
single ventricle anomalies include pulmonary or tricuspid atresia along
with hypoplastic left heart syndromes (4). Together, these represent one
of the largest groups of CHDs that can result in life-threatening disease as
they allow for the mixing of oxygenated and deoxygenated blood and
resultant chronic hypoxia and cyanosis. Additionally, the mixing of blood
can cause volume overload leading to heart failure. Left untreated,
mortality during the first year of life is 70% (5).
Since its introduction in 1971 the Fontan procedure (6) has been the
treatment of choice for single ventricle anomalies. The ultimate goal of the
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procedure is to separate the pulmonary from systemic circulation (7,8).
This involves the diversion of blood into the pulmonary artery directly
from the inferior vena cava (IVC) and is known as the modified Fontan
operation with extra cardiac total cavopulmonary connection (EC TCPC)
(7,8).

Traditionally the Fontan procedure has required a prosthetic vascular
conduit to direct the blood from either the IVC or right atrium (6). Other
CHDs requiring prosthesis include tetrology of Fallot and coarctation of the
aorta. Tetrology of Fallot may require a vascular conduit to establish flow
from the right heart to the pulmonary circuit in a similar manor to the
Fontan procedure (4,9,10,11). Patients may also require a prosthetic valve
to repair a diseased valve (12). Coarctation of the aorta may require a
prosthetic vascular conduit connecting the aorta, distal to the coarctation,
to the left ventricle. Additionally, large atrial or ventricular septal defects
may require prosthetic patches for repair (4).

These procedures and the use of prosthetic grafts have led to rapid
development and improvements in the field of pediatric cardiothoracic
surgery over the last century. However, despite these improvements there
continues to exist significant morbidity and mortality associated with the
repair of CHDs (13,14). There are several reasons for this continuation.
One reason being that advancements in the field have allowed surgeons to
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attempt repairs of the most complex defects (4). A second reason is that
the use of prostheses is not without their pitfalls. Synthetic vascular grafts
currently in use, such as polytetrafluoroethylene, lack the ability to grow.
Additionally they have numerous problems associated with the
development of thrombosis, ectopic calcification, and increased infection
susceptibility (15,16). These problems with synthetic prostheses have
contributed to the continued morbidity and mortality associated with the
repair of CHDs. The lack of prosthesis growth potential often forces the
pediatric patient to endure multiple procedures to upsize the graft as the
patient grows. This exposes the patient to the morbidity and mortality
associated with having to undergo multiple surgeries (14). Two strategies
have been used in an effort to address the lack of growth potential. The
first strategy is to delay surgery until the patient has reached a suitable
size allowing for the implantation of an adult-sized graft (17). A second
option is the implantation of an oversized graft. There are problems
associated with both options. The delay of surgery can result in both
volume overload and chronic hypoxia. Chronic hypoxia has been
associated with developmental delays and failure to thrive (18). Volume
overload may cause cardiac failure. The option to use an oversized graft
often results in turbulent blood flow which increases the risk of
thromboembolic complications which are a leading cause of graft failure
and postoperative morbidity and mortality (17).
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Due to these limitations associated with prosthetic grafts, alternatives that
address these issues could greatly reduce the morbidity and mortality that
is currently associated with surgical repair of CHDs. Tissue-engineered
vascular grafts (TEVGs) have recently been shown to provide an attractive
alternative to prosthetic grafts (19-22). A number of approaches,
including in vivo blood vessel engineering, the use of explanted native
vessels as a living scaffold, using biodegradable polymeric scaffolds onto
which various cells can be seeded prior to implantation, and scaffold-free
approaches have all been investigated (23-25). Unfortunately, none of
these have resulted in the creation of an ideal TEVG.

TEVGs constructed from the seeding of a biodegradable polymeric
scaffolding with cells has revealed promising results. Shinoka et al.
described the first implantations of TEVGs into 25 pediatric patients for
the repair of single ventricle defects in 2001 (26-28). The conduits were
used to create EC TCPC during repair of right ventricle outflow defects or
single ventricle anatomy (29,30). A poly-L-lactide (PLLA) with a
copolymer of lactide and ε-caprolactone (P(CL/LA)) was seeded with
autologous bone marrow mononuclear cells (BM-MNC) harvested on the
day of the surgery. Prior to implantation, seeded conduits were maintained
in culture media for 2-4 h (29). All of the patients that received a TEVG
were evaluated by echocardiography, angiography, computerized
tomography, and/or magnetic resonance imaging. Long-term follow-up has
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revealed graft stenosis in 16% of patients, however this was typically
asymptomatic and all have been treated successfully with stenting and
angioplasty.

Based on these data the use of TEVGs as EC TCPC for the repair of single
ventricle defects is very promising as it has been shown to be both safe and
effective. However, despite these encouraging results, the mechanisms
that underlie the process of graft formation and failure continue to remain
poorly understood. It has been hypothesized that the formation of
neotissue forms from cells that have been seeded onto the biodegradable
scaffold (31). Within this hypothesis these seeded cells are believed to
divide and differentiate into endothelial cells as the scaffold degrades,
resulting ultimately in a purely biological structure without any synthetic
components that has the ability to repair, remodel, and grow in concert
with the patient.

In an effort to better understand these underlying processes we
miniaturized the procedure to allow for a TEVG to be implanted as an IVC
interposition graft in a mouse recipient. Scaffolds were created from the
same synthetic materials and design as used clinically to allow for the
retention of structural, mechanical, and degradation properties.
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Statement:
It was hypothesized that, contrary to the accepted paradigm, autologous
bone marrow-derived mononuclear cells (BMMCs) when seeded onto a
biodegradable scaffold and implanted into mice as tissue engineered
vascular grafts (TEVGs) that seeded cells do not differentiate and divide to
become the neotissue. Furthermore it was hypothesized that the source of
the cells that ultimate become neotissue was either the vasculature
adjacent to the implanted TEVG or cells arising in the host’s own bone
marrow.
Methods:
In the following methods I performed the experiments involved with all
qRT-PCR. This includes the isolation and purification of DNA from mice,
the generation of a reproducible standard curve allowing for the
measurement of mouse genomes/µL, design of the primers and probes, and
the qRT-PCR performed on all explanted mouse TEVGs. All other
experiments were performed by other members of the laboratory.
o Isolation & purification of DNA from GFP + Mice
With the ultimate goal of creating a quantitative Polymerase Chain
Reaction (qPCR) experiment that would allow for the tracking of Green
Fluorescent Protein (GFP)-positive mouse cells in explanted Tissue
Engineered Vascular Grafts (TEVGs), purified whole mouse genomic DNA
was initially needed from both GFP-positive and GFP-negative mice. This

	
  

6	
  

	
  
DNA was needed for the creation of both positive and negative controls to
test and optimize the primers necessary for the reaction. Additionally, the
DNA was required for the creation of a DNA standard curve that would
ultimately allow for the quantification of GFP-positive genomes in the
explanted mouse samples. After concentrating the cells, approximately 5
x 106 GFP-positive Bone Marrow-Derived Mononuclear Cells (BM-MNCs
obtained from C57BL/6 GFP-positive mice were resuspended in 200 uL
lysis buffer (Qiagen, Valenica, CA, USA) and incubated overnight at 56° C
in Proteinase K (12 mAu/reaction) to aid in the DNA extraction. Following
tissue digestion, the whole genomic DNA was then isolated using DNeasy
blood and tissue kit (Qiagen) following the manufacturer’s instructions.
DNA was eluted from the column with 200 uL Buffer AE (Qiagen) and
stored at + 4° C. For use as a negative control in downstream experiments,
DNA was isolated from (non-GFP + mice) in a manor identical to that
previously described. The DNA concentrations were then determined using
the NanoDrop ND-1000 (NanoDrop, Wilmington, DE, USA) per
manufacture’s instruction.
o Standard Curve Generation
The creation of the standard curve is one of the most important aspects of
this experiment. The standard curve allows for the determination of the
amount of DNA present in unknown samples. Using the molecular weight
of the mouse genome at 4 x 1012 grams/mol (32) the DNA concentration
with the units genomes/µL was determined. A working dilution of 20,000
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genomes/µL was created. This allowed for 10-fold serial dilutions to be
performed by placing 20 µL of DNA into 180 µL ddH2O to a concentration
of .2 genome/µL. These dilutions were subsequently used as qPCR
standards by adding 5 µL of each concentration to each reaction resulting
in a standard curve from 1x105 genomes to 1 genome. The standard curve
was run in triplicate in all experiments.
o Design of primers & probe
The gene of interest in this experiment is the GFP gene. Since its discovery
in the 1960s (33) the GFP gene has been modified numerous times
creating multiple different gene sequences. The most popular of these is
the enhanced-GFP (EGFP) mutant (34) that allows for use of the gene in
mammalian cells. In an effort to ensure that the primers designed for this
experiment would be useful across numerous GFP strains the most
common three GFP strains were compared. Using guidelines to ensure a GC content of approximately 20-80%, avoidance of consecutive identical
nucleotides, avoidance of a guanine on the 5’ end, and an ideal melting
temperature of 68° primers were designed that adhered to these rules and
amplified a 93 base pair region that was completely conserved between the
three GFP strains. (Applied Biosystems) The following primers and probe
were chosen: forward, 5’ –ACCACATGAAGCAGCACGACTTCT- 3’; reverse, 5’
–TGTAGTTGCCGTCGTCCTTGAAGA- 3’; probe, 5’AAGGCTACGTCCAGGAGCGCACCAT- 3’. The primers were synthesized by
W.M. Keck Oligonucleotide Synthesis Facility at Yale University. The
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primers were reconstituted in H2O, the amount of which was determined
by multiplying the total nanomoles of primer by four with the product
being the volume of H2O added. Theoretically this should yield a final
primer concentration of 250 uM. The concentrations of the reconstituted
primers were verified by recording the A260 of the primers using the
spectrophotometer (Nanodrop). By calculating the sum of the extinction
coefficients for each primer by using the primer gene sequences the
following equation was used to most accurately determine the primer
concentrations:
A260 = Sum of Extinction Coefficient x Path Length x Concentration/100

As primers are not double stranded and are considerably shorter than
whole genomic DNA this method of determining concentration has greater
accuracy than methods previously described. 1:10 working dilutions were
made in H2O and stored at + 4° C for future use.

The TaqMan (Applied Biosystems) probe was labeled at the 5’ end with 6carboxyfluorescein (FAM). The 3’ end was labeled with TAMRA quencher.
TaqMan probes allow for quantification of specific amplification products.
A fluorescent signal will be detected by the RT-PCR machine only following
the release of the 3’ quencher by the DNA polymerase which occurs only
during amplification of specific DNA sequences.
A SYBR Green (Applied Biosystems, Foster City, CA, USA) qPCR reaction
was performed to test the specificity of the primers. Compared to TaqMan
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probes, real-time PCR with SYBR Green yields similar data. However,
SYBR Green emits a fluorescent signal upon DNA intercalation. This is less
specific than TaqMan as any double stranded DNA, regardless of source, is
capable of SYBR Green intercalation resulting in a false positive signal.
The reaction was carried out with a final volume of 25 µL containing 12.5
µL SYBR Green Master Mix (Applied Biosystems), 0.41 µL (15.3 µM) of
forward and 0.496 µL (12.6 µM) reverse primers, 5 µL template DNA, and
6.59 µL ddH2O. The DNA template consisted of a standard curve as
previously described containing GFP- positive mouse DNA. A negative
control consisting of an identical standard curve created using GFPnegative mouse DNA was run. Additionally, negative controls that
contained all reagents minus template DNA were run. Each SYBR Green
qPCR reaction consisted of the following steps: 10 minutes at 95°C to
activate the polymerase, and 40 cycles of 15 seconds denaturing at 95°C
and 1 minute at 60°C of extension and annealing. Following the completion
of 40 cycles a melting curve was performed to determine purity of the
amplicons. Data were collected at the end of each elongation step and
analyzed with iCycler iQ Real Time Detection System Software (Bio-Rad,
Hercules, CA, USA). To further ensure amplicon specificity products from
SYBR Green PCR were run on a 4% NuSieve 3:1 Plus Agarose Gel (Lonza
Inc., Walkersville, MD, USA) in 1x TAE buffer. 8 µL of PCR product
decreasing to 3 µL in 1 µL increments over successive wells were run with
2 µL loading buffer (Invitrogen, Grand Island, NY, USA). ddH2O was used to
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bring total volume to 10 µL/lane. Gel was imaged using Gel Doc XR+
System (Bio-Rad).
In an effort to ensure that the TaqMan PCR was as sensitive and specific as
possible when applied to the future experiments a number of optimization
experiments were performed. The optimal primer concentration was
investigated by performing PCR reactions with primer concentrations of
125 nM, 250 nM, 500 nM and 1000 nM. PCR was carried out with a final
volume of 20 µL containing 10 µL of TaqMan Universal PCR Master MixUDG (Applied Biosystems), 0.5 µL (10.0 µM) of the TaqMan probe, and 5
µL of DNA. Varying amounts of both forward and reverse primers were
added as described to reach the desired concentrations and ddH2O was
added to bring the final volume of each reaction to 20 µL. The template
DNA used for each reaction was the standard curve in triplicate for each
primer concentration as described above. Each qPCR reaction consisted of
the following steps: 2 minutes UNG incubation at 50°C to remove possible
amplicon contamination, followed by 10 minutes at 95°C to activate the
polymerase. 40 cycles of 15 seconds denaturing at 95°C and 1 minute at
60°C for extention and annealing were performed. Data were collected at
the end of each elongation step and analyzed with iCycler iQ Real-Time PCR
Detection System (Bio-Rad).
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Following determination of the optimal primer concentration the
experiment was repeated as described above to investigate the impact on
the sensitivity and specificity of the qRT-PCR reaction that the presence of
a large amount of background non-specific mouse DNA would have. The
reasoning behind performing this additional experiment lay in an
understanding that the vast majority of DNA present in the experimental
mouse samples would be non-GFP DNA. Because of this, it was imperative
to know the effects on sensitivity that this DNA could potentially play in
our experiments. The qRT-PCR was performed as described previously
however, 1x105 genomes of GFP-negative mouse DNA was added to each
reaction.

Following optimization experiments all TaqMan PCR was carried out with
a final volume of 20 µL containing 10 µL of TaqMan Universal PCR Master
Mix-UDG (Applied Biosystems), 0.33 µL (15.3 µM) of forward and 0.396
µL (12.6 µM) reverse primer, 0.5 µL (10.0 µM) of the TaqMan probe, up to
5 µL of DNA and 3.774 µL of ddH2O. 6000 mouse genomes per sample were
added to each reaction. For consistency, ddH2O was added to each reaction
to bring the final DNA template volume to 5 µL.

Negative controls that contained all reagents except the target DNA, along
with 10-fold serial dilutions of positive control DNA were included in each
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run. Additionally, explanted inferior vena cava from a GFP- negative
mouse was used as a negative control.
o Scaffold Fabrication
The scaffolds for the TEVGs were constructed from a nonwoven
polyglycolic acid (PGA) mesh (Concordia Fibers, Coventry, RI, USA) and a
copolymer sealant solution of poly-L-lactide and ε-caprolactone [P(CL/LA)]
using the dual cylinder chamber molding system as previously described
(35).
o BMMC isolation and TEVG assembly
Bone marrow was collected from the femurs of syngeneic CB57BL/6 mice
(Jackson Laboratories, Bar Harbor, ME, USA). Following purification of the
mononuclear cell component using Histopaque-1086 (Sigma, St. Louis, MO,
USA) centrifugation, 1 x 106 mononuclear cells were manually pipetted
onto the scaffold. The seeded scaffold was incubated in Dulbecco’s modified
Eagle’s medium (Life Technologies, North Andover, MA, USA) overnight
before implantation as described previously (35).
o TEVG Implantation
TEVG implantations were performed using a microsurgical technique. The
scaffolds were inserted into the infrarenal IVC of 6- to 8- wk-old female
mice (Jackson Laboratories as previously described (35,36). All animal
experiments were done in accordance with institutional guidelines for the
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use and care of animals, and the Institutional Review Board at Yale
University approved the experimental procedures described.
o Transgenic Animals
Transgenic inbred C57BL/6 mice that express green fluorescent protein
(GFP) under the control of ubiquitin-C promoter were obtained (Jackson
Laboratories) and bred in our laboratories. All animal procedures were
approved by the Institutional Animal Care and Committee at Yale
University.
o Fate of TEVG-seeded cells
Six- to 8-wk-old (20-25 g) C57BL/6 mice underwent implantation of IVC
interposition grafts using a previously approved protocol, seeded with 1 x
106 GFP+ BMMCs. Mice were killed postoperatively at 6 h (n = 4), 1 d (n =
4), 3 d (n = 4), 7 d (n = 4), and 14 d (n = 4). The grafts were explanted at
predetermined time points to assess for the fate of seeded cells using
quantitative realtime PCR (qRT-PCR) as described previously. Explanted
grafts were placed in lysis buffer (Qiagen). DNA extraction and
quantification was carried out as described above.
o Cell Quantification Assay
The cellularity of each GFP+ BMMC-seeded scaffold was determined by
measuring DNA content with the PicoGreen detection assay (Molecular
Probes, Eugene, OR, USA). At 6 h and 1, 3, and 7 d of incubation, seeded
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scaffold sections were rinsed 3 times in 1 ml PBS, placed in 200 µL of
distilled water, and stored at -80°C. At the time of evaluation, scaffold
sections were thawed at 37°C. A black 96-well plate was loaded with 50 µL
from each sample. A 30 µL aliquot of PicoGreen dye was mixed thoroughly
with 6 ml of Tris-EDTA buffer (pH 7.5), and 50 µL was added to each
sample in the 96-well plate. All samples were performed in triplicate. The
plate was incubated in the dark at room temperature for 10 min.
Fluorescence was measured at 188 nm excitation and 525 nm emission.
The number of cells maintained on each scaffold was determined from a
standard curve generated from a known quantity of mouse BMMCs. A
negative control of unseeded scaffold sections was used for comparison
(28,37,38).
o Cell viability assay
To determine GFP+ BMMC viability following seeding onto scaffold sections
and incubation at 6 h and 1, 3, and 7 d, a CellTiter 96 AQueous
nonradioactive cell proliferation assay (Promega BioSciences, San Luis
Obispo, CA, USA) was performed. After seeding, all scaffold sections were
incubated in 2 ml of RPMI 1640 (1% penicillin/streptomycin and 10% fetal
bovine serum) for the respective incubation times. Medium was changed
every 2 d. Following incubation, the scaffold sections were washed 3 times
with 1 ml PBS and the assay reagent, tetrazolium compound 3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salts (MTS), and an electron coupling reagent,
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phenazine methosulfate, was added to each scaffold section in a 1:4 ration
with medium and allowed to incubate for 4 h at 37°C. After 4 h, a 100 µL
aliquot of each sample was added to a clear 96-well plate, and the
absorbance at 490 nm was read. The relative cell viability was determined
by the ratio of absorbance from the seeded scaffold sections incubated at
different time points.
o Bone Marrow Transplantation
After myeloablation with 900 cGy total body irradiation using a 137Cs
source, 6-wk-old female wild-type C57BL/6 mice received a tail vein
injection of 5 x 106 unfractionated nucleated bone marrow cells (BMCs
harvested from age-matched, sex-mismatched (male) GFP+ transgenic
mice, as described previously (39). We confirmed engraftment of the bone
marrow 1 mo after bone marrow transplantation by determining the
percentage of GFP+ cells on peripheral blood using FACS. Subsequently,
TEVGs (n = 57) were implanted as IVC interposition grafts. Specimens for
immunostaining (n = 27) were explanted at postoperative d 3 (n = 6), 7 (n
= 6), and 14 (n = 5), wk 10 (n = 5), and mo 6 (n = 5), and specimens for
qRT-PCR (n =30) were explanted at postoperative d 3 (n = 6), 7 (n = 6), and
14 (n = 6), wk 10 (n = 6), and mo 6 (n = 6).
o Composite Graft Construction
The vena cava was harvested from a male mouse. Sections of the vena cava
(1mm) were anastomosed to the distal end of a scaffold. The composite
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scaffold was then seeded and incubated as described above. The composite
TEVG was implanted in a female host (n = 8). Specimens were harvested at
postoperative d 7 (n = 2) and 14 (n = 2), wk 10 (n = 2), and mo 6 (n = 2).

o Histology
Explanted grafts were pressure fixed in 10% formalin overnight and then
embedded in paraffin or glycolmethacrylate using previously published
methods (35,36). Sections were stained with hematoxylin and eosin.
o Immunohistochemistry
Primary antibodies included rat-anti-mouse Mac-3 (BD Bioscience, San
Jose, CA, USA), F4/80 (AbD Serotec, Raleigh, NC, USA), mouse-anti-human
von Willebrand Factor (vWF; Dako), rabbit-anti-mouse to c-kit (Abcam),
mouse-anti-mouse to Sox-2 (R&D Systems). Antibody binding was detected
using appropriate biotinylated secondary antibodies, followed by binding of
streptavidin-HRP and color development with 3,3-diaminobenzidine
(Vector, Burlingame, CA, USA). Nuclei were then counterstained with
hematoxylin. For immunofluorescence detection, a goat=anti-rabbit IgGAlexa Fluor 568 (Invitrogen, Carlsbad, CA, USA) or a goat-anti-mouse IgGAlexa Fluor 488 (Invitrogen) was used with subsequent 4’,6-diamidino-2phenylindole nuclear counterstaining.
o Fluorescent in situ hybridization (FISH)
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FISH was performed on paraffin sections using digoxigenin-labeled mouse
Y chromosome probe detected using a rhodamine-conjugated antibody to
digoxigenin (Roche Diagnostics, Mannheim Germany) as described
previously (15, 16). Counting of Y+ nuclei was accomplished by
systematically examining the FISH-stained tissue, field by field, at x 40,
using a Zeiss Axiovert 200M Fluorescence/Live cell Imaging Microscope
(Carl Zeiss Imaging Solutions, Thornwood, NY, USA). Digital images were
acquired using the Zeiss LSM510 confocal computer system (Carl Zeiss
Imaging Solutions). Images were pseudocolored using image processing
software (Adobe Photoshop, San Jose, CA, USA). Cell counts were obtained
by first counting all of the Y chromosome-positive (YChr+) cells in a defined
area on the tissue and then counting the total number of cells in that area
using the immunostained photographs.
Results:
qRT-PCR is a sensitive and specific method for the quantification of
mouse DNA
The initial SYBR Green qRT-PCR experiments revealed that the sensitivity
of the GFP primers was approximately 10 genomes. GFP negative mouse
DNA was used in this experiment as a negative control and revealed no
amplification. To ensure that detected amplification was specific for the
desired region of the GFP gene a melting curve on the PCR products was
performed at the conclusion of the 40th PCR cycle. This revealed a
consistent melting curve at 86°C at all DNA concentrations supporting that
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amplification was specific (data not shown). To further investigate the
specificity of the qRT-PCR reaction the PCR products were run on a 4%
agarose gel to allow adequate resolution of small amplicons. A single
amplification product was visualized at 98 bp which corresponded with the
expected amplicon size based on the GFP sequence and primer pair used
(data not shown). TaqMan qRT-PCR experiments revealed similar reaction
sensitivities of 10 genomes. Primer concentrations of 1000 nM
consistently resulted in increased sensitivity and thus all subsequent
reactions contained a final concentration of 1000 nM for both the forward
and reverse primer. The addition of 1 x 105 mouse genomes to each qRTPCR reaction revealed no decrease in sensitivity or specificity when
compared to reactions carried out without the additional mouse DNA.
TEVGs form neovessels resembling native veins
Syngeneic BMMCs seeded onto miniaturized PGA-P(CL/LA) scaffolds were
subsequently implanted onto the IVC of CB57BL/6 mice. Histologic
examination of explanted grafts at 6 months revealed the presence of a
mature laminated structure that consisted of an endothelialized intimal
layer along with a smooth muscle layer consistent with native vein tissue
(Fig. 1B). Scaffold material was found to be completely degraded by 6
months. Additionally, three-dimensional computed tomography
angiography of TEVGs at 6 months revealed no evidence of stenosis,
aneurismal dilation, or thrombosis (Fig. 1A).
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Fate of TEVG-seeded cells
qRT-PCR performed for the GFP gene present in BMMCs seeded onto the
TEVG in vitro demonstrated that the greatest amount of GFP DNA was
maximal at 6 hrs following overnight incubation (Fig. 2A). The GFP DNA
present on the scaffold decreased after 1 day of incubation. These in vitro
data suggest that seeded cells decrease in number during the initial
incubation process. This is most likely secondary to a failure for the cells to
adequately adhere to the scaffolding material and thus are washed off with
medium changes. Cell viability and metabolic activity of the seeded BMMCs
were both demonstrated to increase over a 7 day incubation period (Fig.
2B). This supports the notion that the loss of cells demonstrated over the
course of incubation is due to the cells failure to adhere to the scaffolding
material and not due to BMMC cell death in vitro.

Following 7 days of incubation TEVGs (n=30) that had been seeded with
GFP-labeled syngeneic BMMCs were implanted onto the IVC of 6- to 8week-old C57Bl/6 mice. The TEVGs were harvested at 6 hour, and 1, 3, 7,
and 14 days. At each time point the percentage of GFP DNA was quantified.
We found that the seeded GFP-labeled syngeneic BMMCs disappeared with
the increase in host-derived macrophages on the scaffold. Graft
immunofluorescence revealed the presence of GFP-labeled cells at 6 hours
and 1 and 3 days. However, at 7 days post implantation no GFP cells were
identified on the scaffold (Fig. 2C). These data were further supported by
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qRT-PCR for GFP DNA on explanted TEVGs. Over the course of 14 days
following graft implantation the GFP concentration on the graft was shown
to decrease rapidly from a high of 173 genomes/µL at 6 hours postimplantation to 0.12 genomes/µL at 14 days post-implantation. The
percentage of GFP+ cells per TEVG was found to decrease from 4.37% at 6
hours to 0.02% at 14 days (Fig. 2E). In an effort to demonstrate that this
decrease in cell percentages was due to the loss of GFP+ cells, and not
simply a result of a dilutional effect caused by the influx of host cells the
data were standardized. This standardization further recapitulated that
initial GFP+ cells were indeed lost following implantation of the graft.
BMCs are not the ultimate source of vascular neotissue
Building on the aforementioned results a series of experiments were
designed in an effort to identify the source of the cells that ultimately come
to populate the implanted scaffold. The role of host BMCs in neotissue
formation was investigated by creating chimeras of rescued lethally
irradiated C57BL/6 female mice with sex-mismatched male GFP+ total
BMCs from transgenic GFP-labeled mice. Donor cell engraftment within the
surviving recipients was determined at 5 weeks following bone marrow
transplantation and FACS analysis of peripheral blood GFP-labeled mice
demonstrated 97.74% circulating GFP+ cells in a positive control mouse
(Fig. 3A), 0.49% in a negative control mouse (Fig. 3B), and 94.06%
reconstitution in transplanted mice (Fig. 3C). TEVGs were implanted in
female mice following successful creation of the chimeras. Following graft
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implantation the mice were killed at 3, 7, and 14 days, 10 weeks, and 6
months. Grafts were evaluated histologically and YChr+ cells were
demonstrated in the graft wall at 3 and 7 days following implantation.
These cells were primarily male-derived macrophages as determined by
colocalization of YChr+ and F4/80 antibody cells. These YChr+ BMCs
continued to increase in number and at day 14 days both endothelial cells
and smooth muscle cells began to appear. The cells comprising the
developing neotissue were positive for vWF and SMA and negative for
YChr (Fig. 4D, E). A confluent neointima comprised of endothelial cells and
neomedia comprised of smooth muscle cells were present by week 10.
These layers were both negative for YChr+ cells. Finally, the last time point
at 6 months post-implantation revealed a smooth muscle layer composed
of calponin+ YChr- cells with a endothelial layer of vWF+ YChr- cells (Fig.
4A, B). The original scaffold material was nearly completely degraded with
the presence of scant inflammatory cells positive for MAC-3 and YChr (Fig.
5B). The infiltration of BM-derived YChr+ cells in the implanted graft wall
increased during the initial 10 weeks following implantation, however by
the 6 month time point the presence of these cells was greatly decreased
(Fig. 4C). These observations provided by immunohistochemistry were
further recapitulated quantitatively by using qRT-PCR for GFP DNA within
the graft over an identical time course (Fig. 4D). These data revealed that
following graft implantation the initial scaffold infiltrates were
macrophages originating in the bone marrow. Following this initial
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inflammatory infiltrate the presence of endothelial and smooth muscle
cells lacking colocalization of cell markers specific to each tissue type with
the Y chromosome were present with a decreasing presence of
inflammatory cells (Fig. 4E).
Neovessel formation arises from ingrowth of vascular cells from the
neighboring blood vessel
While the bone marrow appears responsible for an initial inflammatory
infiltrate following graft implantation, the source of the endothelial and
smooth muscle cells was demonstrated in previous experiments to be
derived of cells not of bone-marrow-origin. An experiment was designed to
investigate the possibility that the graft neotissue’s origins lay in the cells
of the blood vessel adjacent to the implanted graft. A composite vascular
graft was created by anastomosing a segment of syngeneic male IVC with a
TEVG scaffold (Fig. 5A). The entire composite vascular graft (n=8) was
implanted into a female host. The grafts were harvested at 7 and 14 days,
10 weeks, and 6 months post-implantation. After paraffin embedding all
grafts were cut longitudinally so that male IVC (donor), TEVG, and female
(host) IVC were included. FISH specific to Y chromosome was performed
on the explanted grafts. At days 7 and 14 following graft implantation the
majority of the graft were populated by MAC 3+/YChr- cells (host origin).
At these time points no confluent endothelial or smooth muscle cell layers
were identified. However, at day 14 a non-confluent endothelial and
smooth muscle layer positive for vWF and calponin respectively were
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noted. The confluence of these cell layers was greatly increased by 10
weeks postimplantation. At 6 months postimplantation the neovessel was
composed of a confluent neointima, neomedia and a neoadventitia. Using
FISH it was revealed that cells comprising the neotissue adjacent to the
male IVC (donor) contained the highest percentage of YChr+ cells (Fig. 5B,
C). The neotissue adjacent to the female (host) IVC lacked YChr+ cells.
These, along with the previously discussed findings, suggest that the cells
that ultimately come to permanently populate the graft and create the
viable neovessel have their origins in the vessel adjacent to the implanted
scaffold. This is contrary to previous proposed mechanisms that
hypothesized that the source of cells ultimately creating the neovessel
were derived from the seeded cells or from bone marrow progenitor cells.
Instead it suggests a mechanism involving a locally mediated process of in
growth of endothelial and smooth muscle cells from the surrounding native
vessel.
Discussion:
As the clinical trial performed by Shinoka has shown that the use of TEVGs
in the repair of single ventricle is both effective and safe with results that
clearly represent an improvement over the standard of care (29). As
previously stated, despite the efficacy and excellent safety profile of TEVGs
in these repairs, stenosis has continued to plague grafts requiring
subsequent stenting or angioplasty to correct. With this knowledge we
returned to the laboratory in an effort to elucidate the mediators of
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stenosis in implanted TEVGs. This study’s purpose was specifically to
determine the source of the cells that ultimately create the neotissue in
implanted TEVGs. In effort to make this determination, the origins of
vascular neotissue cells in a syngeneic immunocompetent mouse recipient
using bone marrow chimeric hosts and composite vascular implants was
investigated. To mimic the high-flow, low-pressure venous setting that one
would encounter in clinical applications related to the repair of congenital
heart defects the PGA-P(CL/LA) tubular scaffolds were miniaturized and
seeded with syngeneic BMMCs prior to implantation into the mouse IVC.
Previous work published by the laboratory was validated in the
observation that the seeded cells from the TEVG following implantation
disappeared precipitously. These data were of increased clinical relevance
in this study in that an immune-competent murine model was used.
Additionally, to track the fate of the seeded BMMCs used in this study,
TEVGs that were implanted were constructed by seeding the scaffolds with
GFP-labeled syngeneic BMMCs. These scaffolds were harvested over a time
course of 2 weeks. At each time point the percentage of GFP-positive DNA
was quantified by using RT-PCR. Findings were consistent to a previous
study using a human into mouse xenogeneic model in that the seeded cells
disappeared after implantation as the scaffold became populated by hostderived cells. These cells that initially populate the implanted scaffold were
identified as F4/80-expression macrophages. While this decrease in the
percentage of GFP-positive cells present on the TEVGs could have been
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simple secondary to a dilutional effect due to the increased cell density
caused by infiltrating macrophages, this possibility was ruled out by
standardizing the data to reflect cell density. It was again observed, as has
been described in previous studies, that over the course of 6 months
following implantation the scaffold material completely degrades and the
TEVGs display a vascular architecture similar to that of native vein.
The results of the previous experiments clearly show that contrary
to the traditional hypothesis, the cells seeded onto the TEVG prior to
implantation do not differentiate, divide and subsequently becoming the
vascular neotissue observed at 6 months. Instead the source of the cells
that ultimately comprise the vascular neotissue must have an alternate
source. The two hypotheses that we proposed regarding the source of these
cells were the host’s bone marrow-derived cells or the cells comprising the
adjacent vasculature itself. In an effort to address the possibility that the
source of the cells were the host’s bone marrow-derived cells, TEVGs were
implanted into female mice that had undergone bone marrow
transplantations with syngeneic male bone marrow. These TEVGs were
harvested at numerous time points over the course of 6 months. Harvested
grafts were analyzed using FISH for the Y chromosome. A number of other
cellular markers were included as well such as F4/80 for macrophages,
calponin for smooth muscle cells, and vWF for endothelial cells. These
experiments revealed that the macrophages seen immediately infiltrating
the TEVG following graft were positive for Y chromosome indicating that
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they are derived from the bone marrow. However, at later time points after
the development of vascular neotissue, there was no evidence of
colocalization of either smooth muscle cell markers or endothelial cell
markers with the marker for the Y chromosome. These data suggest that
while the initial host response to the implanted TEVG in the form of
infiltrating macrophages is derived from the host’s bone marrow, the cells
that ultimately become the neotissue are from an alternate source.
The second proposed hypothesis that we investigated was that the
source of the cells that ultimately comprise the vascular neotissue is the
neighboring blood vessel itself. A composite vascular graft created by
anastomosing a segment of syngeneic male IVC proximally to the TEVG.
The entire TEVG with the anastomosed male IVC was implanted into a
female host. As in previous experiments these were harvested over a 6
month time period. The explanted grafts were analyzed using FISH to
identify Y chromosome presence along with the presence of endothelial
and smooth muscle cells. Contrary to previous experiments both
endothelial cells and smooth muscle cells were found to contain the Y
chromosome. Additionally, the percentage of cells that were positive for
the Y chromosome was noted to be greatest adjacent to the implanted male
IVC segment. As one moves distally along the implanted TEVG a decline in
cells positive for the Y chromosome was noted. These data suggest that the
source of cells ultimately comprising the neotissue arise from the in
growth of cells from the adjacent blood vessel segments both proximally
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and distally to the implanted TEVG. It is likely these cells are already fully
differentiated prior to ingrowth, however our experiments cannot rule out
the possibility that there exists a rare population of stem cells that reside
within the adjacent vascular segments. In an effort to investigate this
possibility immunohistochemistry staining was performed for both stem
cells and progenitors. This staining provided no evidence for the presence
of non-differentiated cells further suggesting that the source of the cells is
fully differentiated neighboring endothelial and smooth muscle cells.
Our study has allowed for a significantly increased understanding of
the process of TEVG formation following implantation. The most valuable
information that our study provides to the understanding of the
development of TEVGs is that in our mouse model the cells that become the
intima and media of the neovessel are derived from the vessel wall of
proximal and distal neighboring vasculature. The finding that cells seeded
onto the biodegradable scaffold prior to implantation are not directly
responsible for the growth of cells on the scaffold represents a paradigm
shift with respect to the previous hypothesis.
The next step is to use these discoveries in the creation of a secondgeneration TEVG with the goal of significantly decreasing the graft stenosis
rate. While grafts have been shown to remain patent following
implantation without cell-seeding, the rate of stenosis and subsequent graft
failure is much greater in these non-seeded TEVGs. Although our data
suggest the role of seeded cells is secondary to the ultimate formation of
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TEVG neotissue it is possible that they help facilitate an accelerated host
response and thus expedited formation of the neovessel. This acceleration
could alone account for the decrease in stenosis and graft failure due to a
decrease in the amount of time that the host’s pro-coagulant blood
products are exposed to the scaffold material and the possible turbulent
flow that may result. Future experiments should be focused on identifying
critical molecular mediators of stenosis. Once these have been identified,
grafts could be designed with improved long-tem patency. Secondly, the
molecular mechanisms controlling vascular neotissue formation should be
elucidated. Because our experiments have demonstrated that seeded cells
are not directly responsible for graft population, it can be deduced that the
role that the seeded cells is of paracrine nature. By identifying mediators
of this paracrine response it would be possible to create grafts that elute
cytokines, thus obviating the need for cell-seeding.
Preliminary studies have supported this hypothesis finding that
seeded grafts recruit significantly more macrophages suggesting that this
recruitment is of importance in the formation of patent neovessels.
Additionally, MCP-1 along with IL-1β were detected in abundance in seeded
grafts. Subsequent studies in which scaffolds containing alginate
microspheres were implanted into mice revealed that the controlled
release of MCP-1 allowed by the alginate microspheres prevented graft
stenosis in the absence of cell seeding. These results suggest that the MCP1 released following implantation recruit host monocytes to the graft
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which participate in the formation of vascular neotissue by means of an
inflammation-mediated process of vascular remodeling (40). Further
studies further characterizing this process will help to further elucidate
the molecular players involved with the aim of creating improved TEVGs
in the future.
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Figure 1. A) CT angiogram of a TEVG IVC interposition graft 6 mo after
implantation. TEVG is colored blue. B) Representative photomicrographs
of immunohistochemical characterization of the native IVC compared with
the TEVG 6 mo after implantation (hematoxylin and eosin, x100; CD31
and Cal, x400).
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Figure 2. A) DNA assay of scaffolds from 0 h to 7 d of in vitro incubation
showed increased number of cells in first 24 h and loss of cells after 72 h.
B) MTS assay of scaffolds from 0 h to 7 d in vitro incubation showed initial
increase in metabolic activity followed by steady state. C) In vivo tracking
using immunofluorescence (x630) demonstrated GFP+ cells within the
graft at 6 h and 1 and 3 d but no cells at 7 d postimplantation. D) These
findings were corroborated by qRT-PCR for the GFP gene from TEVGs
(n=30) seeded with GFP+ cells, implanted in GFP-negative hosts, and
harvested between 6 h and 14 d after implantation. Level of detection is 10
genomes/µl. E) Percentage of GFP-labeled cells per TEVG standardized for
cell density decreased form 4.37% at 6 h to 0.02% at 14 d. Data are
expressed as means ± SD.
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Figure 3. A-C) FACS analysis of GFP+ mouse as positive control (A),
C57BL/6 mouse for negative control (B), and engraftment 5 wk posttransplantation (C). D) Schematic demonstrating components and
orientation of photomicrographs. E, F) Confocal microscopic images of
TEVG implanted into female host that had undergone transplantation with
male bone marrow harvested 14 d after implantation, demonstrating no
colocalization with the Y chromosome (Y-chromosome FISH and either
endothelial cells (EC; vWF, x630; E) or smooth muscle cells (SMC;
calponin, x630; F).
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Figure 4. A)Schematic demonstrating components and orientation of
photomicrographs. B) Confocal microscopic images of TEVG implanted into
female host that had undergone transplantation with male bone marrow
harvested 6 mo after implantation, demonstrating colocalization of
macrophages (MAC) and the Y-chromosome (Y-chromosome FISH) but no
colocalization with the Y chromosome (Y-chromosome FISH) and either
endothelial cells (vWF) or smooth muscle cells (Calponin; x400). C)
Numbers of infiltrating BM-derived Y chromosome (Y-chromosome FISH)
cells (bone marrow cells/high power field) in the graft wall increased up to
10 wk, while graft degradation was occurring, but at 6 mo
postimplantation, these cells markedly decreased. D) This was quantified
and corroborated using qRT-PCR for GFP DNA within the graft over a 6 mo
period. E) Confocal microscopic image of triple staining of a 6 mo neovessel
with normal IVC configuration with single-layer neointima (EC;vWF/light
blue), neomedia (SMC; calponin/green), and neoadventitia with scattered
inflammatory cells (male;Ychr/red).
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Figure 5. Schematic demonstrating composite TEVG (n=8) created by
anastomosis of a syngeneic male IVC with a TEVG, implanted into a female
host and harvested at 6 mo after implantation, and the percentage of cells
with Y-chromosome as a function of distance from the male IVC. A)
Confocal microscopic images demonstrating colocalization of endothelial
cells (VWF) and Y chromosome (Y chromosome FISH;x400). C)
Photomicrographs demonstrating colocalization of smooth muscle cells
(calponin) and Y chromosome (Y-chromosome FISH; x400).
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